Andrew Johns
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Andrew Johns' research focuses on the clinical outcomes and toxicities associated with immune checkpoint inhibitors (ICIs) in cancer patients. His work has investigated the incidence, risk factors, and survival impacts of ICI-related adverse events, including thrombocytopenia and hepatitis. Johns has also examined prognostic markers, such as serum albumin, for predicting treatment response to ICIs and chemoimmunotherapy. His research includes studies on specific patient populations, such as older adults with advanced cancer, and explores the potential for SARS-CoV-2 mRNA vaccines to sensitize tumors to ICI therapy. Additionally, his work has involved comparing different methods for evaluating immunotherapy-related adverse events, such as manual chart review versus ICD claims data. Johns has an h-index of 12 with 74 total publications and 525 total citations.
Metrics
- h-index: 12
- Publications: 74
- Citations: 525
Selected Publications
-
Efficient Self-Driving: A Study on the Behavioral Cloning based Autonomous Navigation (2025)
Collaboration Network
Top Collaborators
- Efficient Self-Driving: A Study on the Behavioral Cloning based Autonomous Navigation
- Efficient Self-Driving: A Study on the Behavioral Cloning based Autonomous Navigation
- Efficient Self-Driving: A Study on the Behavioral Cloning based Autonomous Navigation
Similar Researchers
Based on overlapping research topics